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Infectious retroviruses are important causative agents of human and animal disease. They all possess a characteristic enzyme, reverse transcriptase (RT), and can thus be detected by assays for this activity (1, 2) . However, the current tests are insensitive when compared with virus-specific methods. Detection of human immunodeficiency virus type 1 (HIV-1) by RT assay, for example, is 100 times less sensitive than by antigen (Ag) assay (3) . Polymerase chain reaction (PCR) is again orders of magnitude more sensitive (4) .
The narrow detection range of sequence-based tests such as PCR is, however, a disadvantage when detection of retroviruses in general is the aim. Attempts to detect uncharacterized retroviruses by the use of PCR with primers from conserved genomic regions have been met with some success but lack sensitivity and, therefore, require prior isolation and multiplication of the virus in a suitable host cell line usually difficult to find (5) . Here, we report the development of an ultrasensitive RT assay capable of detecting retroviruses at a sensitivity hitherto reserved to virus-specific sequence amplification.
tained from R. C. Gallo (National Institutes of Health, Bethesda, MD). HTLV-IIIB was also produced in C81-66-45 (hence called C81-66-45/HIV-1). The HTLV-1 producer MT-2 was from I. Miyoshi (Kochi Medical School, Kochi, Japan), the cloned HTLV-2 producer 76D9 was from J. Jendis (our laboratory), and the uninfected monocytoid cell line RC2A was from P. Stoeckbauer (Center for Hematology and Blood Transfusion, Prague). All lines were kept in RPMI 1640 medium plus 10% fetal bovine serum, 100 international units of penicillin G per ml, 100 jig of streptomycin per ml, 2.5 Mg of amphotericin B per ml (all from GIBCO), and 5% interleukin 2 (IL-2) (Cellular Products).
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enhanced RT assay (PERT assay), while not significantly affecting sensitivity. 
RESULTS
The PERT assay uses PCR for the selective enhancement of the MS2 cDNA synthesized by RT activity. The procedure described in Materials and Methods represents the results of many experiments performed to define conditions under which the assay would work at the desired high sensitivity and specificity.
In this procedure it was critical to guarantee that the reagents used did not contain amplifiable DNA, that such DNA was not introduced with the sample, and that no cDNA was produced from the RNA template by endogenous RT activity associated with the assay reagents themselves. Genomic RNA of MS2 was chosen for template since the replication of this phage does not involve a DNA intermediate (10) . A systematic contamination of the template by amplifiable DNA or inadvertent introduction of such DNA by a sample was thus impossible. As a heteropolymer the MS2 RNA had the further advantage of being much less efficiently used by eukaryotic DNA polymerases than the synthetic homopolymeric templates usually employed for RT tests (7) . To prevent degradation by RNases present in the test sample, the template was stabilized by placental RNase inhibitor.
In experiments shown in Fig. 1 , the assay reagents were systematically examined for contaminating amplifiable DNA and for endogenous RT activity, using ELISA-based product analysis. In Fig. 1A , the reverse transcription step of the procedure was omitted and the assay reagents were directly submitted to PCR. In the absence of MS2 RNA, the reagents Medical Sciences: Pyra et al.
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Medical Sciences: Pyra et al. Using the complete PERT assay procedure, the reagents of the reverse transcription step were tested for product generation in the absence or presence of a low activity of MuLV RT (Fig. 1B) . In the absence of RNase inhibitor, the assay showed the expected results: absence of signal in the absence of RT and good signal with RT, respectively. However, with RNase inhibitor 1, purified from human placenta, a strong signal was produced and the added RT activity could no longer be distinguished from the background. Less endogenous activity was found with the recombinant RiNase inhibitor 2 (the human placenta protein expressed in E. coli). No product was generated when the template was digested by RNase A prior to incubation with RNase inhibitor 1, indicating that neither RNase A nor the RNase inhibitor was contaminated by amplifiable DNA.
In conclusion, these experiments showed that the assay reagents were free of amplifiable DNA, but that the RNase inhibitor and the Taq DNA polymerase both contained RT activity, which raised the background and, consequently, the detection limit of the assay. Therefore, all batches of RNase inhibitor were screened for RT activity and only those with low activity were used. In addition, the template was routinely digested by RNase A prior to amplification. These measures guaranteed a background sufficiently low to permit detection of very low RT activities.
The sensitivity of this system was assessed in a model experiment in which serial dilutions of recombinant MuLV RT were tested in parallel by conventional RT test and PERT assay (Fig. 2A) . The detection limit of the RT test was between 10-2 and 10-3 unit. By contrast, the PERT assay clearly detected 10-9 unit, while 10-10 unit was within background. Thus, the detection limit of the PERT assay was 106 to 107 times lower than that of the conventional test.
The dilution experiment also showed that below 10-7 unit the signal obtained with the PERT assay was proportional to the RT activity and that thus, in this range, the test could be used for quantitation. The detection limit and quantitative range both depended on the number of amplification cycles (Fig. 2B ): 10 cycles rendered RT detection 100 times more sensitive than the conventional procedure. An increase to 25 cycles resulted in an additional 105-fold increase in sensitivity. With >25 cycles, the increasing background precluded a further gain in sensitivity (not shown).
The capability of the assay to identify retroviruses present at numbers too low to be detected by conventional RT assay was assessed in a sucrose gradient density banding experiment performed with supernatants from HTLV-i-producing MT-2 cells and a PBMC coculture control originating from two normal blood donors, respectively. The MT-2 supernatant was diluted 1:1000 into the PBMC supernatant prior to sample pretreatment and banding, while the PBMC supernatant was used undiluted. Gradient fractions were analyzed by PERT assay (Fig. 3A) . No PERT activity was detected in any of the fractions of the PBMC coculture. In MT-2 supernatant, the activity banded at a single peak at a density of 1.14 g/ml. RNA PCR confirmed that this peak corresponded to HTLV-1 particles (Fig. 3B) . Conventional RT assay performed with fractions of the diluted MT-2 supernatant indi- cated absence of activity, while positive and negative controls showed the expected results (data not shown).
Based on these results, a procedure for the detection of filterable particle-associated RT was developed, to be used as a screening assay for retroviruses. Sample fluids were precleared by high-speed centrifugation and filtered. Particulate material was then pelleted by ultracentrifugation and analyzed by PERT assay. In Southern blot analysis (Fig. 4A) , strong signals were obtained with supernatants from cell lines producing HIV-1, HTLV-1, or HTLV-2, while with the chosen film exposure no signals were detected with undiluted supernatants from nonproducers C81-66-45 and RC2A. Undiluted supernatants from unstimulated PBMC or PHAstimulated PBMC cultures were also negative, while the PBMC coculture of an HIV-1-infected patient was positive. After longer film exposure, however, faint reactions were also detected with cultures considered uninfected, in particular with stimulated or unstimulated PBMC cultures (data not shown). Distinct signals were found when plasma samples from patients infected with HIV-1, HIV-2, or HTLV-1 or serum samples from cats infected with FeLV or FIV were assayed (Fig. 4B) . By contrast, a blood donor plasma and the serum of a SPF cat were negative. RNA PCR of virus pelleted from plasma of the HTLV-1-infected patient gave a weak- positive result (not shown), in concordance with the relatively weak signal obtained in the PERT assay. All of five additional plasma samples from unselected blood donors were negative by PERT assay while all of five additional plasma samples from HIV-1-infected patients were strongly positive (Fig. 4C) .
Since cellular DNA polymerases represent a possible source of false positivity, their interference with the PERT assay was assessed in cell cultures established from whole blood of healthy donors. Cultures from HIV-1-infected individuals were used as positive controls. Fig. 5 shows a representative experiment in which WHB cells from four donors and three HIV-1 positives were maintained under the various culture conditions described in Materials and Methods, including WHB cocultures (Fig. SA) , stimulated WHB cocultures (Fig. 5B) , and stimulated WHB cultures (Fig. SC) . Supernatants were tested weekly for HIV-1 Ag (upper panels) and for RT activity by PERT assay using ELISA-based product analysis (lower panels). Fig. 5 Based on these findings, cutoffs of positivity (mean + 5 SD) were calculated and used for interpretation of cultures from HIV-1 positives. All were, at least initially, PERTpositive. By contrast, Ag p24 assay completely failed to detect virus in stimulated WHB cocultures and in two ofthree stimulated WHB cultures.
Similar results were seen with PBMC cocultures from three other HIV-1 patients and three other blood donors (data not shown). Together, these experiments showed that the PERT assay was definitely more sensitive than the Ag assay and correctly identified all HIV-infected cultures. On the other hand, the cocultures from a total of 14 individuals (2 per coculture) considered uninfected showed very little activity, even under conditions of extensive cell death and, consequently, the release of cellular polymerases.
DISCUSSION
Association with filterable particle-associated RT activity is a hallmark of infectious retroviruses and of diagnostic importance. The PERT assay now adds the high sensitivity of PCR to the broad detection range of the RT assay. The result is an assay capable of detecting, at unprecedented sensitivity and specificity, RT and thus a wide variety of human and animal retroviruses that may have but little sequence homology in common (Fig. 4) .
The low background ( Fig. 1 ) permitted 25 rounds of cDNA amplification resulting in the detection of <10-9 unit of RT activity ( Fig. 2A) . Given the specific activity of >40,000 units/mg and the Mr of71,000 ofthe MuLV RT used, the 10-9 unit represents 2.1 x 102 RT molecules, which corresponds to 3-11 virions based on estimates of20-70 RT molecules per virion in avian and mammalian type C retroviruses (12) (13) (14) . Direct comparative testing of serial dilutions of HIV-1 by PERT assay and RNA PCR indicated a detection limit of about 10 virions for both methods (unpublished data).
The high specificity of the PERT assay is documented by the demonstration that negative controls yielded negative results (Fig. 4) and control cell supernatants showed minimal activity even under massive stimulation by alloantigen, PHA, PWM, and LPS, which resulted in extensive cell death (Fig.  5) , and by gradient analysis of MT-2 or PBMC coculture supernatants showing absence of particle-associated activity from fractions other than those containing virions (Fig. 3) . Furthermore, testing of culture supernatants with elevated activity in the conventional RT test confirmed that the PERT assay is considerably more specific: of 29 samples with RT activity .20,000 cpm (i.e., 10-15 times the method background), 27 were negative by PERT assay and the 2 positives were also positive for HIV-1 Ag (not shown).
The high sensitivity, specificity, and broad range of agents to which it is sensitive predispose the PERT assay for use as a universal screening assay for all agents associated with RT activity. The procedure permits the direct detection of such agents in primary materials, thereby obviating the need for virus cultivation. In addition to the known agents, the test may identify hitherto unrecognized retroviruses. Further studies will need to show whether other retroelements-e.g., hepatitis B virus-can also be detected. The PERT assay may further be used for quantitation of virus load, for evaluation of virus inactivation procedures, or to determine the susceptibility of a virus to RT inhibitors.
